Intravascular ultrasound (IVUS) in percutaneous coronary interventions – summary of key articles While angiography is routinely used for assessment of.

Slides:



Advertisements
Similar presentations
TAVOLA ROTONDA Quale Ruolo Clinico e Quale Rimborso per la Franctional Flow Reserve? Correlazioni anatomo-funzionali FFR vs IVUS Luigi Vignali, Parma Bologna.
Advertisements

IVUS Use during Left Main PCI improve Immediate and Long Term Outcome Where is the Evidence? E Murat Tuzcu, MD, FACC Professor of Medicine Vice Chairman.
FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY
CORONARY PRESSURE MEASURENT AND FRACTIONAL FLOW RESERVE
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
Multi-vessel disease and intracoronay physiology Combat MI 2009 Kees-joost Botman MD, PhD Catharina hospital Eindhoven Heart Institute The Netherlands.
左主干分叉病变治疗策略的选择 Left main bifurcation: what is the best choice? Lei Ge, MD Department of Cardiology, Zhongshan Hospital, Fudan University.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prospective Application of Pre-Defined Intravascular.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Coronary Anatomy and Stenting Technique.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Characteristics and Long-Term Outcomes of Percutaneous.
Real-world clinical experience with an everolimus eluting platinum chromium stent with an abluminal biodegradable polymer – a report from the Swedish Coronary.
Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
Jose M. de la Torre Hernández … in behalf of the 3D investigators
Total Occlusion Study of Canada (TOSCA-2) Trial
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
Latvian Centre of Cardiology real-life registry
IVUS, FFR, OCT- Which Should I Use For PCI?
on behalf of the ABSORB II Investigators
Clinical Usefulness of Post-Stenting FFR
The MASS-DAC Study.
(DES)+BVS +DCB for long diffuse LAD disease
David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research
9:00 AM-9:05 AM, Tuesday, Oct. 31; Room 201/203
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
When IVUS? When FFR? Assessing Intermediate Lesions
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
BVS Expand: First Results of Wide Clinical Applications
Overview of the Clinical Utility of IVUS to Optimize PCI
Stent Thrombosis Rates in Contemporary Clinical Practice: Insight from a Large Australian Multi-centre Registry BP Yan*, TJ Kiernan, SJ Duffy, DJ Clark,
OCT-Guided PCI What needs to be done to establish criteria?
On behalf of J. Belardi, M. Leon, L. Mauri,
The Hidden Cost of Underutilizing PCI for Chronic Total Occlusions
Stenting of Coronary Arteries in Non Stress/Benestent Disease
Catheter-Based Treatment of Coronary Artery Disease
Long-term follow-up of the DIABETES I (DIABETes and sirolimus Eluting Stent) trial: P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín,
American College of Cardiology Presented by Dr. Stephan Windecker
Giuseppe Biondi Zoccai, MD
3-Year Clinical Outcomes From the RESOLUTE US Study
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
Efficacy of Xience/Promus versus Cypher to rEduce Late Loss in stENT
AN INTERNATIONAL COLLABORATIVE META-ANALYSIS ON 1,274 PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Impact of Platelet Reactivity Following Clopidogrel Administration
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
FOR DISTRIBUTION BY MEDTRONIC OFFICE OF MEDICAL AFFAIRS ONLY.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Presented at TCT 2006.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Impact of Diabetes Mellitus on Long-term Outcomes in the
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Atlantic Cardiovascular Patient Outcomes Research Team
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
The American College of Cardiology Presented by Dr. A. Abazid
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

Intravascular ultrasound (IVUS) in percutaneous coronary interventions – summary of key articles While angiography is routinely used for assessment of CAD, it is not always able to determine the clinical significance of lesions in vessels with complex anatomy such as the LM. It displays a two dimensional image of contrast-filled lumen, which does not allow an accurate assessment of plaque. This presentation describes the key studies in IVUS-guided LM interventions over the last 10 years. Prepared by Radcliffe Cardiology 29 June 2016

Abbreviations CABG: coronary artery bypass grafting CAD: coronary artery disease FFR: fractional flow reserve IVUS: intravascular ultrasound LAD: left anterior descending artery LCX: left circumflex artery LM: left main coronary artery MACE: major adverse cardiac events MLA: minimal lumen area MLD: minimal lumen diameter PCI: percutaneous coronary intervention

Intravascular Ultrasound-Derived Minimal Lumen Area Criteria for Functionally Significant Left Main Coronary Artery Stenosis Park SJ, Ahn JM, Kang SJ, et al JACC Cardiovasc Interv, 2014;7:868-74.

IVUS-Derived MLA Criteria for Functionally Significant LM Stenosis, Park et al, 2014 Background: Follow-up to previous study with larger patient population Methods: 112 patients with isolated ostial and shaft LM stenosis IVUS imaging and FFR measurement before intervention This study also performed additional subgroup analysis to investigate whether patient characteristics affected the MLA cutoff

IVUS-Derived MLA Criteria for Functionally Significant LM Stenosis, Park et al, 2014 Results: At maximal hyperaemia, 59% of the lesions had had an FFR ≤0.80. Factors significantly associated with FFR ≤0.80: plaque rupture, (OR: 4.47; 95% CI: 1.356-14.8; p=0.014) BMI (OR: 1.19; 95% CI: 1.00-1.41; p=0.05) Age(OR: 0.95; 95% CI: 0.90-1.00; p=0.031) IVUS MLA (OR: 0.37; 95% CI: 0.25-0.56; p < 0.001). Best cutoff value for FFR of ≤0.80 was 4.5 mm2.

IVUS-Derived MLA Criteria for Functionally Significant LM Stenosis, Park et al, 2014 Conclusions: In patients with isolated ostial and shaft intermediate LMCA stenosis, an IVUS-derived MLA of ≤4.5 mm2 is a useful index of an FFR of ≤ 0.80 Since the FFR is the most sensitive indicator of ischemia, it remains the gold standard but IVUS-derived MLA may help in clinical decision-making in patients with LM lesions.

Clinical impact of intravascular ultrasound guidance in drug-eluting stent implantation for unprotected left main coronary disease: pooled analysis at the patient-level of 4 registries de la Torre Hernandez JM, Baz Alonso JA, Gomez Hospital JA, et al., JACC Cardiovasc Interv, 2014;7:244-54

Clinical impact of IVUS guidance in DES implantation for unprotected LM CAD, de la Torre Hernandez et al, 2014 Background: Limited evidence for clinical benefit for IVUS guidance in LM disease Methods: Analysis of 4 large Spanish registries, n=1670 505 patients who had DES implantation with IVUS guidance propensity score-matched with 505 patients who received DES without IVUS guidance The role of IVUS guidance in PCI of the LM remains controversial and regulatory guidelines give only a Class IIB recommendation for the use of IVUS guidance during LM PCI.

Clinical impact of IVUS guidance in DES implantation for unprotected LM CAD, de la Torre Hernandez et al, 2014 Results: At 3 year follow-up survival free of cardiac death, MI, and TLR: 88.7% vs 83.6%; p = 0.04 for IVUS vs overall population In subgroups with distal LM lesions, endpoint achieved in 90% vs 80.7%, p=0.03 Definite and probable stent thrombosis 0.6% vs 2.2%, p=0.4 IVUS-guided revascularization was identified as an independent predictor for major adverse events in the overall population (HR 0.70, 95% CI 0.52 to 0.99; p=0.04) and in the subgroup with distal lesions (HR 0.54, 95% CI 0.34 to 0.90; p=0.02).

Clinical impact of IVUS guidance in DES implantation for unprotected LM CAD, de la Torre Hernandez et al, 2014 Conclusions: IVUS guidance during PCI is associated with better outcomes in patients with LM disease undergoing revascularization with DES Study may not have accounted for other confounding factors in assessing the clinical benefits associated with IVUS guidance. However, it was well powered statistically

Mariani J, Jr., Guedes C, Soares P, et al. Intravascular Ultrasound Guidance to Minimize the use of Iodine Contrast in Percutaneous Coronary Intervention: The MOZART Randomized Controlled Trial Mariani J, Jr., Guedes C, Soares P, et al. JACC Cardiovasc Interv, 2014;7:1287-93. MOZART = Minimizing contrast utiliZAtion with IVUS guidance in coRonary angioplasTy

The MOZART trial, Mariani et al, 2014 Background: Angiography requires the use of large amounts of iodine contract agent Risk of contrast-induced acute kidney injury and volume overload Methods: n=83, randomized to IVUS or angiography-guided PCI Most patients had diabetes and many had long, calcified, bifurcated, and complex lesions Angiography requires the use of iodine contrast agent, and may cause contrast-induced acute kidney injury. The use of contrast is also potentially problematic in patients at risk of volume overload i.e. excess fluid in the blood. The use of IVUS during coronary angioplasty should result in reduced patient exposure to contrast

The MOZART trial, Mariani et al, 2014 Results IVUS group had threefold reduced usage of contrast dose compared with angiography group (64.5 ml vs 20.0 ml respectively, p<0.001) In-hospital and 4-month outcomes were not different between patients who received angiography-guided and IVUS-guided PCI

The MOZART trial, Mariani et al, 2014 Conclusions IVUS imaging should be considered for patients at high risk for contrast-induced acute kidney injury or volume overload undergoing coronary angioplasty Patients who had undergone recent catheterization, were taking nephrotoxic agents, or had unstable or unknown renal function, were excluded from the study. A cost-effectiveness study would be useful to determine whether the increased procedural cost of IVUS would be offset by the reduced contract use and ultimate decrease in complications

Chieffo A, Latib A, Caussin C, et al Am Heart J, 2013;165:65-72 A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: The AVIO trial Chieffo A, Latib A, Caussin C, et al Am Heart J, 2013;165:65-72 AVIO = Angiography Vs. IVUS Optimization

The AVIO trial, Chieffo et al, 2013 Background DES use is associated with risk of late stent thrombosis Post-procedural MLD predicts risk of stent thrombosis Methods n=284, all with complex lesions Randomized 1:1 to IVUS or angiography-guided procedures Stent thrombosis may be a consequence of stent underexpansion. Since IVUS has shown to be useful in optimising stent placement and expansion, it has the potential to improve outcomes in DES implantation . Complex lesions defined as one of the following: long lesions (>28 mm); chronic total occlusions [CTO], i.e., a total blockage lasting more than 3-months; lesions involving a bifurcation; small vessels (≤ 2.5mm) and patients requiring 4 or more stents

The AVIO trial, Chieffo et al, 2013 Results Post-procedure MLD was significantly higher in the IVUS group (2.70 ± 0.46 vs 2.51 ± 0.46 mm; p = 0.0002) At 24 months follow-up, no difference between the two groups for the incidence of MACE, cardiac death, MI, TLR or TVR. Only 48% of lesions treated using IVUS guidance met AVIO criteria. Of those that did not meet criteria, no benefit was reported for IVUS. Failure to meet AVIO criteria may have been due to the criteria being too strict or operator concern at undertaking aggressive post-dilatation procedures.

The AVIO trial, Chieffo et al, 2013 Conclusions IVUS-guided DES implantation resulted in a larger post-procedural MLD than angiography-guided procedures, with no difference in the incidence of MACE at 24 months. A larger study is warranted

Use of IVUS guided coronary stenting with drug eluting stent Use of IVUS guided coronary stenting with drug eluting stent. A systematic review and meta-analysis of randomized controlled clinical trials and high quality observational studies Klersy C, Ferlini M, Raisaro A, et al Int J Cardiol, 2013;170:54-63

Systematic review and meta-analysis, Klersy et al, 2013 Background Lack of data on outcomes in IVUS-guided PCI in the era of DES Methods 268 abstracts considered 12 studies selected: 3 randomized controlled trials 9 high quality observational studies 18,707 patients.

Systematic review and meta-analysis, Klersy et al, 2013 Results Median follow-up 20 months IVUS associated with: 20% decreased risk of MACE (p < 0.001) 40% decreased risk of death (p < 0.001) 41% decreased risk of MI (p = 0.001) 50% decreased risk of thrombosis Larger post-procedure MLD (standardized mean difference = 0.15, p = 0.014) No effect on thrombosis

Systematic review and meta-analysis, Klersy et al, 2013 Conclusions IVUS guidance in DES implantation, performed in large volume centres, reduces MACE by reducing mortality and MI, possibly by reducing thrombosis rather than restenosis rate.

Effect of Intravascular Ultrasound-Guided vs Angiography-Guided Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial Hong SJ, Kim BK, Shin DH, et al. JAMA, 2015;314:2155-63

The IVUS=XPL trial, Hong et al, 2015 Background Limited clinical trial data to support the use of IVUS-guided drug eluting stent (DES) implantation. Earlier studies used 1st generation DES but 2nd generation exclusively used now. Methods n=1,400 Randomized 1:1 to receive either IVUS-guided or angiographic-guided everolimus-eluting stent implantation IVUS-XPL = Impact of Intravascular Ultrasound Guidance on Outcomes of Xience Prime Stents in Long Lesions

The IVUS=XPL trial, Hong et al, 2015 Results At 1 year, IVUS group had a 48% reduced risk of MACE compared with the angiography group (2.9% vs 5.8%, p = 0.007) Patients who did not meet IVUS criteria for optimum stent deployment had a significantly higher incidence of MACE compared with those who met IVUS criteria (4.6% vs 1.5%, p = 0.020) No statistically significant differences in cardiac death, target lesion–related MI, or stent thrombosis Lack of benefits in terms of death, MI and ST may reflect the superior performance of everolimus-eluting stents compared with first-generation DES

The IVUS=XPL trial, Hong et al, 2015 Conclusions The use of IVUS-guided everolimus-eluting stent implantation, compared with angiography-guided stent implantation, resulted in a significantly lower rate of MACE at 1 year

Comparison of intravascular ultrasound guided versus angiography guided drug eluting stent implantation: a systematic review and meta-analysis Zhang YJ, Pang S, Chen XY, et al BMC Cardiovasc Disord, 2015;15:153.

Systematic review and meta-analysis, Zhang et al, 2015 Background Lack of clinical trial evidence is limiting the use of IVUS to guide DES implantations Methods Meta-analysis of 20 clinical studies that compared clinical outcomes between IVUS-guided and angiography-guided DES implantation 3 randomized clinical studies and 17 observational registry studies

Systematic review and meta-analysis, Zhang et al, 2015 Results IVUS guided procedures were associated with a significantly lower risk of: MACE (OR 0.77, 95 % CI 0.71- 0.83, P < 0.001 death (OR 0.62, 95 % CI 0.54-0.71, p < 0.001) stent thrombosis (OR 0.59, 95 % CI: 0.47-0.73, P < 0.001) In a subanalysis of patients with complex lesions or acute coronary syndrome (ACS), IVUS was associated with significantly reduced risk of MACE, death and stent thrombosis, with a pronounced benefit of IVUS in terms of death

Systematic review and meta-analysis, Zhang et al, 2015 Conclusions IVUS guidance is associated with improved clinical outcomes, especially in patients with complex lesions admitted with ACS.

IVUS in bifurcation stenting: what have we learned? Legutko J, Yamawaki M, Costa RA, et al. EuroIntervention, 2015;11 Suppl V:V55-8.

IVUS in bifurcation stenting: what have we learned? Bifurcation lesions are difficult to assess by angiography because the lesion is often obscured by overlapping side branches IVUS allows assessment of all lesion segments.

IVUS in bifurcation stenting: what have we learned? Pre-procedure, IVUS assessment allows: accurate measurement of lumen and vessel assessment of the extent and distribution of plaque severity of hardening and changes in the artery size detection of other disease not detectable by angiography such as diffuse disease and stenosis of the LM MLA can be used to guide clinical decision-making: cut-off value 4.5 – 6.0 mm2 predicts myocardial ischemia

IVUS in bifurcation stenting: what have we learned? During procedure IVUS allows: control of wire re-crossing across the side branch optimization of the positioning and expansion of the stent assessment of the lesion coverage by the stent problems arising at the edge of the stent e.g. secondary lesions No guidelines – clinical decision-making at the discretion of the operator

IVUS in bifurcation stenting: what have we learned? A number of studies have reported improved clinical outcomes following IVUS-guided procedures A recent meta-analysis involving over 25,000 patients, has concluded that IVUS-guided procedures result in a significantly lower risk of death, MI, stent thrombosis and target lesion revascularization compared with procedures that did not use IVUS Need for large randomized controlled studies

Outcomes With Intravascular Ultrasound-Guided Stent Implantation Outcomes With Intravascular Ultrasound-Guided Stent Implantation. A Meta-Analysis of Randomized Trials in the Era of Drug-Eluting Stents Elgendy IY, Mahmoud AN, Elgendy AY, et al Circ Cardiovasc Interv, 2016;9:e003700.

Meta-Analysis of Randomized Trials in the Era of DES Elgendy et al, 2016 Background Need for a meta-analysis including only randomized trials that evaluated clinical outcomes associated with IVUS-guided PCI compared with angiography-guided PCI using DES Methods 7 RCTs 3,192 patients

Meta-Analysis of Randomized Trials in the Era of DES Elgendy et al, 2016 Results Mean follow-up 15 months IVUS-guided PCI was associated with: 40% decreased risk of MACE (p < 0.0001) 40% reduced risk of ischaemia or TLR (p=0.003) 54% reduced risk of cardiovascular death (p=0.05) 51% reduced risk of stent thrombosis (p=0.04) Also better post-procedural outcomes (MLD and diameter stenosis)

Meta-Analysis of Randomized Trials in the Era of DES Elgendy et al, 2016 Conclusions In the era of DES, IVUS-guided PCI is superior to angiography-guided PCI in reducing the risk of major adverse cardiac events Authors recommended that IVUS guided procedures are routinely considered in the revascularization of diffuse coronary lesions

The Role of Virtual Histology Intravascular Ultrasound in the Identification of Coronary Artery Plaque Vulnerability in Acute Coronary Syndromes Sinclair H, Veerasamy M, Bourantas C, et al Cardiol Rev, 2016

Virtual Histology IVUS in ACS Sinclair et al, 2016 Grayscale IVUS constructs images based on amplitude of reflected ultrasound waves VH-IVUS spectral pattern recognition to analyse the frequency and amplitude of the waves, obtaining a more accurate image of tissue subtypes

Virtual Histology IVUS in ACS Sinclair et al, 2016 Use Assessment of coronary artery plaques Classification of plaques However studies small and largely based on animal models

Virtual Histology IVUS in ACS Sinclair et al, 2016 Use of VH-IVUS to predict clinical outcomes PROSPECT study: 697 patients with ACS The following predicted MACE: plaque burden ≥70% presence of VH-TCFAs median dense calcium area ≥0.2mm2 TCFA = inflamed thin-cap fibroatheroma

Virtual Histology IVUS in ACS Sinclair et al, 2016 Use of VH-IVUS to predict clinical outcomes VIVA study: 100 patients with angina The following predicted MACE: plaque burden >70% presence of VH-TCFAs Remodelling index

Virtual Histology IVUS in ACS Sinclair et al, 2016 Use of VH-IVUS to predict clinical outcomes ATHEROMA-IVUS study: 581 patients with stable angina or ACS The following predicted MACE: plaque burden >70% presence of VH-TCFAs MLA ≤4mm2

Virtual Histology IVUS in ACS Sinclair et al, 2016 Other imaging modalities Integrated backscatter-IVUS generates colour images iMap - produces images based on pattern recognition of the radio frequency (RF) signals A comparison of these to techniques found discrepancies between them

Virtual Histology IVUS in ACS Sinclair et al, 2016 Conclusions VH IVUS is useful for identifying high-risk plaque features and vulnerable lesions in patients with ACS in research settings Its use has also has added to the body of evidence that VH-TCFAs adversely affect patient outcomes